By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Cigna, CVS Health downgraded on competition in pharmacy benefit manager business
Stocks

Cigna, CVS Health downgraded on competition in pharmacy benefit manager business

News Room
Last updated: 2023/08/20 at 2:16 PM
By News Room
Share
3 Min Read
SHARE

© Reuters.

Investing.com — Health care stocks were mixed on Friday after analysts downgraded Cigna and CVS Health citing concerns about competition in the pharmacy benefit manager business.

Edward Jones cut its ratings for Cigna Corp (NYSE:) and CVS Health Corp (NYSE:) to hold from buy. The move comes after CVS lost part of a contract with insurer Blue Shield of California, which has selected Amazon.com (NASDAQ:) and a collection of other companies to take on the tasks of a pharmacy benefit manager.

The analysts estimate that Cigna’s pharmacy benefit manager business contributed two-thirds of the insurer’s profit last year, and they noted that while it is just one contract for CVS, Blue Shield of California’s move highlights the growing competitive threat in the business.

While Blue Shield of California’s multi-player model – for example Amazon will provide home delivery of drugs, while other companies will manage claims, and another will negotiate prices – rather than the familiar bundled approach will be complicated to implement. CVS will continue to provide Blue Shield of California with specialty drug services.

But, the analysts said, the new model could weigh on CVS shares. “The BCS contract could also encourage customers to be more aggressive in negotiating future PBM contracts with industry players,” they wrote.

Shares of Cigna closed up 2%, while shares of CVS were flat.

For Cigna, the analysts pointed to opportunities in MedicareAdvantage and biosimilars, which are generic versions of complex injectable drugs. “The health insurance market is growing due to the expansion of MA, and we believe Cigna can increase marketshare,” they said.

As for CVS, the analysts noted that it is also a diverse model, with a retail drugstore business, Aetna health insurance, specialty drug services, and patient care services. That is helping it transform into a one stop shop for health care.

“Over the long term, this integrated strategy should lead to accelerating earnings growth for the company,” they said.

Read the full article here

News Room August 20, 2023 August 20, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Inside Intel’s new Arizona fab, where the chipmaker’s fate hangs in the balance

Watch full video on YouTube

3 elements of an AI bubble. 🗯️

Watch full video on YouTube

Poland races to build bomb shelters

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

How Gen Z Is Reviving Legacy Brands

Watch full video on YouTube

Market insiders on what investors need to know about Fed uncertainty, inflation, volatility

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?